Diakonos Oncology's Experimental Immunotherapy Shows 90% Survival Improvement in Glioblastoma Phase I Trial
Key Insights
Diakonos Oncology (search)'s experimental immunotherapy demonstrated nearly 90% of glioblastoma (search) patients achieving extended survival in phase one trials.
The treatment works by extracting DNA from patients' tumors and tricking the immune system (search) into mounting an aggressive viral-like response against cancer cells.
Patient Jeremy Herschaft, diagnosed with glioblastoma (search) in December 2024, is thriving after receiving the personalized immune-based therapy despite the disease's typically poor one-year survival outlook.
Diakonos Oncology (search) has reported promising early results from a phase one trial of an experimental immunotherapy for glioblastoma (search), with nearly 90% of patients achieving extended survival. The personalized immune-based therapy represents a potential breakthrough for patients facing one of the most aggressive forms of brain cancer.
Novel Mechanism Targets Tumor DNA
The treatment employs a unique approach that involves extracting DNA from patients' tumors to create a personalized therapy. "What we're doing is essentially tricking the immune system (search) into thinking the patient has a virus and when the immune system feels like it's under viral attack, it responds very aggressively," explained Mike Wicks, CEO of Diakonos Oncology (search).
This mechanism leverages the body's natural antiviral response to mount an aggressive attack against cancer cells, offering a novel strategy for treating glioblastoma (search), which Dr. William Decker, Professor at Baylor College of Medicine, describes as "a devastating disease with a one-year survival."
Patient Success Story Highlights Treatment Potential
Jeremy Herschaft, who was diagnosed with a malignant brain tumor (search) in December 2024, exemplifies the therapy's potential impact. Despite glioblastoma (search)'s typically poor prognosis, Herschaft is thriving after participating in the experimental treatment. "Success for me would obviously be to live many future years. But even if that doesn't happen, even if I only have a short amount of time, what's amazing is my data could help someone else," Herschaft said.
Safety and Tolerability Focus
The company emphasizes that the treatment aims to provide both efficacy and safety. "Our goal is to make it a lot more than a few months," said Jay Hartenbach, President & COO of Diakonos Oncology (search). "Not only are we providing a treatment that has the potential to extend dramatically or save a person's life, but do it in a manner that's tolerable, that's safe."
Expansion to Additional Cancer Types
Building on the glioblastoma (search) results, Diakonos Oncology (search) is expanding its research program to test similar cell therapies on pancreatic and skin cancers. This broader application suggests the company's approach may have utility across multiple cancer types, potentially addressing unmet medical needs in various oncology indications.
The phase one trial results mark an important milestone for patients facing glioblastoma (search), a cancer type with limited treatment options and poor survival outcomes. The nearly 90% survival improvement rate in early trials represents a significant advancement in the field of cancer immunotherapy.